- Home
- KNSA vs VCYT Comparison
KNSA vs VCYT Comparison
Compare KNSA & VCYT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNSA
- VCYT
- Stock Information
- Founded
- KNSA 2015
- VCYT 2006
- Country
- KNSA United Kingdom
- VCYT United States
- Employees
- KNSA N/A
- VCYT N/A
- Industry
- KNSA Biotechnology: Pharmaceutical Preparations
- VCYT Medical Specialities
- Sector
- KNSA Health Care
- VCYT Health Care
- Exchange
- KNSA Nasdaq
- VCYT Nasdaq
- Market Cap
- KNSA 2.1B
- VCYT 2.1B
- IPO Year
- KNSA 2018
- VCYT 2013
- Fundamental
- Price
- KNSA $27.12
- VCYT $24.21
- Analyst Decision
- KNSA Strong Buy
- VCYT Buy
- Analyst Count
- KNSA 6
- VCYT 9
- Target Price
- KNSA $39.33
- VCYT $39.89
- AVG Volume (30 Days)
- KNSA 980.0K
- VCYT 971.8K
- Earning Date
- KNSA 07-29-2025
- VCYT 08-06-2025
- Dividend Yield
- KNSA N/A
- VCYT N/A
- EPS Growth
- KNSA N/A
- VCYT N/A
- EPS
- KNSA N/A
- VCYT 0.41
- Revenue
- KNSA $481,166,000.00
- VCYT $463,393,000.00
- Revenue This Year
- KNSA $37.21
- VCYT $12.55
- Revenue Next Year
- KNSA $5.32
- VCYT $9.79
- P/E Ratio
- KNSA N/A
- VCYT $56.75
- Revenue Growth
- KNSA 59.45
- VCYT 23.42
- 52 Week Low
- KNSA $17.82
- VCYT $19.73
- 52 Week High
- KNSA $30.69
- VCYT $47.32
- Technical
- Relative Strength Index (RSI)
- KNSA 43.14
- VCYT 37.24
- Support Level
- KNSA $28.19
- VCYT $22.61
- Resistance Level
- KNSA $29.58
- VCYT $27.91
- Average True Range (ATR)
- KNSA 0.93
- VCYT 1.04
- MACD
- KNSA -0.13
- VCYT -0.28
- Stochastic Oscillator
- KNSA 3.15
- VCYT 29.96
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
About VCYT Veracyte Inc.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.